Boston Scientific Comprehensive Income 2010-2024 | BSX
Boston Scientific comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Boston Scientific comprehensive income for the quarter ending September 30, 2024 was $-0.128B, a 155.41% decline year-over-year.
- Boston Scientific comprehensive income for 2023 was $0.049B, a 81.78% decline from 2022.
- Boston Scientific comprehensive income for 2022 was $0.269B, a 2.28% increase from 2021.
- Boston Scientific comprehensive income for 2021 was $0.263B, a 27.05% increase from 2020.
| Boston Scientific Annual Comprehensive Income (Millions of US $) |
|
|---|---|
| 2023 | $49 |
| 2022 | $269 |
| 2021 | $263 |
| 2020 | $207 |
| 2019 | $270 |
| 2018 | $33 |
| 2017 | $-59 |
| 2016 | $1 |
| 2015 | $88 |
| 2014 | $144 |
| 2013 | $106 |
| 2012 | $-33 |
| 2011 | $-138 |
| 2010 | $-129 |
| 2009 | $-43 |
| Boston Scientific Quarterly Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024-09-30 | $-128 |
| 2024-06-30 | $164 |
| 2024-03-31 | $132 |
| 2023-12-31 | $49 |
| 2023-09-30 | $231 |
| 2023-06-30 | $208 |
| 2023-03-31 | $178 |
| 2022-12-31 | $269 |
| 2022-09-30 | $532 |
| 2022-06-30 | $433 |
| 2022-03-31 | $222 |
| 2021-12-31 | $263 |
| 2021-09-30 | $238 |
| 2021-06-30 | $237 |
| 2021-03-31 | $254 |
| 2020-12-31 | $207 |
| 2020-09-30 | $151 |
| 2020-06-30 | $131 |
| 2020-03-31 | $168 |
| 2019-12-31 | $270 |
| 2019-09-30 | $138 |
| 2019-06-30 | $78 |
| 2019-03-31 | $87 |
| 2018-12-31 | $33 |
| 2018-09-30 | $25 |
| 2018-06-30 | $-16 |
| 2018-03-31 | $-128 |
| 2017-12-31 | $-59 |
| 2017-09-30 | $-51 |
| 2017-06-30 | $-53 |
| 2017-03-31 | $-46 |
| 2016-12-31 | $1 |
| 2016-09-30 | $-99 |
| 2016-06-30 | $-70 |
| 2016-03-31 | $35 |
| 2015-12-31 | $88 |
| 2015-09-30 | $81 |
| 2015-06-30 | $104 |
| 2015-03-31 | $142 |
| 2014-12-31 | $144 |
| 2014-09-30 | $110 |
| 2014-06-30 | $42 |
| 2014-03-31 | $72 |
| 2013-12-31 | $106 |
| 2013-09-30 | $56 |
| 2013-06-30 | $82 |
| 2013-03-31 | $45 |
| 2012-12-31 | $-33 |
| 2012-09-30 | $-112 |
| 2012-06-30 | $-87 |
| 2012-03-31 | $-79 |
| 2011-12-31 | $-138 |
| 2011-09-30 | $-132 |
| 2011-06-30 | $-123 |
| 2011-03-31 | $-119 |
| 2010-12-31 | $-129 |
| 2010-09-30 | |
| 2010-06-30 | |
| 2010-03-31 | $-18 |
| 2009-12-31 | $-43 |
| 2009-09-30 | |
| 2009-06-30 | |
| 2009-03-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $139.837B | $14.240B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $194.797B | 24.85 |
| Stryker (SYK) | United States | $139.395B | 31.41 |
| EssilorLuxottica (ESLOY) | France | $110.104B | 0.00 |
| Medtronic (MDT) | Ireland | $103.429B | 15.36 |
| Lonza Group Ag (LZAGY) | Switzerland | $43.664B | 0.00 |
| Haleon (HLN) | United Kingdom | $41.193B | 26.76 |
| GE HealthCare Technologies (GEHC) | United States | $38.725B | 20.09 |
| ResMed (RMD) | United States | $34.324B | 28.21 |
| Terumo (TRUMY) | Japan | $28.025B | 39.58 |
| Koninklijke Philips (PHG) | Netherlands | $24.269B | 18.58 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.811B | 13.25 |
| Insulet (PODD) | United States | $19.068B | 75.93 |
| Baxter (BAX) | United States | $15.022B | 9.77 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.471B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.568B | 32.52 |
| BellRing Brands (BRBR) | United States | $9.145B | 36.79 |
| Demant (WILYY) | Denmark | $8.596B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.666B | 15.49 |
| Haemonetics (HAE) | United States | $3.851B | 18.79 |
| ICU Medical (ICUI) | United States | $3.779B | 35.98 |
| Prestige Consumer Healthcare (PBH) | United States | $3.656B | 18.18 |
| Perrigo (PRGO) | Ireland | $3.326B | 9.79 |
| Envista Holdings (NVST) | United States | $3.198B | 23.82 |
| QuidelOrtho (QDEL) | United States | $3.077B | 19.81 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| Neogen (NEOG) | United States | $2.678B | 30.90 |
| GN Store Nord (GNNDY) | Denmark | $2.593B | 16.63 |
| LeMaitre Vascular (LMAT) | United States | $2.104B | 51.14 |
| Green Thumb Industries (GTBIF) | United States | $1.564B | 27.37 |
| AtriCure (ATRC) | United States | $1.531B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.364B | 9.75 |
| InMode (INMD) | Israel | $1.335B | 8.03 |
| BioLife Solutions (BLFS) | United States | $1.234B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.225B | 0.00 |
| Owens & Minor (OMI) | United States | $1.071B | 8.37 |
| Curaleaf Holdings (CURLF) | Canada | $0.942B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.812B | 14.32 |
| CeriBell (CBLL) | United States | $0.750B | 0.00 |
| Evolus (EOLS) | United States | $0.633B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.600B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.551B | 24.31 |
| Surmodics (SRDX) | United States | $0.549B | 0.00 |
| Omeros (OMER) | United States | $0.512B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.459B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.423B | 0.00 |
| ZimVie (ZIMV) | United States | $0.372B | 31.37 |
| Valneva SE (VALN) | France | $0.369B | 0.00 |
| Quanterix (QTRX) | United States | $0.363B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.310B | 29.44 |
| Biote (BTMD) | United States | $0.307B | 6.73 |
| Cerus (CERS) | United States | $0.293B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.282B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.270B | 18.10 |
| Canopy Growth (CGC) | Canada | $0.267B | 0.00 |
| High Tide (HITI) | Canada | $0.250B | 103.00 |
| Zynex (ZYXI) | United States | $0.249B | 52.20 |
| Aurora Cannabis (ACB) | Canada | $0.227B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.224B | 3.15 |
| Utah Medical Products (UTMD) | United States | $0.207B | 14.26 |
| MacroGenics (MGNX) | United States | $0.200B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.198B | 0.00 |
| Brainsway (BWAY) | Israel | $0.177B | 94.00 |
| TerrAscend (TSNDF) | Canada | $0.164B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.157B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.137B | 17.21 |
| Quipt Home Medical (QIPT) | United States | $0.129B | 0.00 |
| Jin Medical (ZJYL) | China | $0.126B | 0.00 |
| Veru (VERU) | United States | $0.114B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.88 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.096B | 0.00 |
| InterCure (INCR) | Israel | $0.076B | 0.00 |
| INLIF (INLF) | $0.068B | 0.00 | |
| Rockwell Medical (RMTI) | United States | $0.067B | 34.67 |
| Apyx Medical (APYX) | United States | $0.060B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.059B | 0.00 |
| Exagen (XGN) | United States | $0.056B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.052B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.051B | 0.00 |
| ImmuCell (ICCC) | United States | $0.046B | 0.00 |
| Modular Medical (MODD) | United States | $0.046B | 0.00 |
| Safety Shot (SHOT) | United States | $0.037B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 13.30 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |